Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brandon Nicolay

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
ACS Medicinal Chemistry Letters|February 20, 2020
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of GliomaZenon Konteatis, Erin Artin, Brandon Nicolay, et al.
Blood Advances|May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLSung Choe, Hongfang Wang, Courtney D DiNardo, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 16, 2025
Mutant <i>IDH1</i> cooperates with <i>NPM1c</i> or <i>FLT3</i><sup>ITD</sup> to drive distinct myeloid diseases and molecular outcomesTakashi Sakamoto, Julie Leca, Xin Zhang, et al.
Cancer Discovery|December 1, 2021
Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in CholangiocarcinomaMeng-Ju Wu, Lei Shi, Juan Dubrot, et al.
Journal of Hepatology|October 29, 2022
Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironmentNatascha Roehlen, Marion Muller, Zeina Nehme, et al.
The Journal of Experimental Medicine|March 24, 2021
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemiaLucille Stuani, Marie Sabatier, Estelle Saland, et al.
Nature Medicine|July 11, 2018
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarateLukas Bunse, Stefan Pusch, Theresa Bunse, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
ACS Medicinal Chemistry Letters|February 20, 2020
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of GliomaZenon Konteatis, Erin Artin, Brandon Nicolay, et al.
Blood Advances|May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLSung Choe, Hongfang Wang, Courtney D DiNardo, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 16, 2025
Mutant <i>IDH1</i> cooperates with <i>NPM1c</i> or <i>FLT3</i><sup>ITD</sup> to drive distinct myeloid diseases and molecular outcomesTakashi Sakamoto, Julie Leca, Xin Zhang, et al.
Cancer Discovery|December 1, 2021
Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in CholangiocarcinomaMeng-Ju Wu, Lei Shi, Juan Dubrot, et al.
Journal of Hepatology|October 29, 2022
Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironmentNatascha Roehlen, Marion Muller, Zeina Nehme, et al.
The Journal of Experimental Medicine|March 24, 2021
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemiaLucille Stuani, Marie Sabatier, Estelle Saland, et al.
Nature Medicine|July 11, 2018
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarateLukas Bunse, Stefan Pusch, Theresa Bunse, et al.
Pageof 2